Dr. Popplewell is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
600 Celebrate Life Pkwy.
Newnan, GA 30265
Education & Training
- Memorial Sloan Kettering Cancer CenterFellowship, 1995 - 1998
- Temple University HospitalResidency, 1992 - 1995
- University of Louisville School of MedicineClass of 1992
Certifications & Licensure
- GA State Medical License 2023 - 2026
- IL State Medical License 2023 - 2026
- CA State Medical License 1998 - 2025
- AZ State Medical License 2002 - 2017
- PA State Medical License 1993 - 1995
- American Board of Internal Medicine Hematology
Clinical Trials
- Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma Start of enrollment: 2023 Sep 29
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- Magrolimab plus rituximab with or without chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma.Joseph E Maakaron, Adam Asch, Leslie Popplewell, Graham P Collins, Ian W Flinn
Blood Advances. 2024-11-26 - 1 citationsMagrolimab plus rituximab in relapsed/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1/2 trial.Amitkumar Mehta, Leslie Popplewell, Graham P Collins, Sonali M Smith, Ian W Flinn
Blood Advances. 2024-11-26 - Prognostic significance of fludeoxyglucose positron emission tomography delta radiomics following bridging therapy in patients with large B-cell lymphoma undergoing CA...Colton Ladbury, Claire Hao, William Tyler Watkins, Sagus Sampath, Jeffrey Wong
Frontiers in Immunology. 2024-01-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: